SLSThe headline: still a clinical story
SELLAS Life Sciences spent its second-quarter update doing what biotech companies do best: reminding you that today’s stock price is basically a vote on tomorrow’s trial data. The company reported Q2 2026 financial results and said it still has plenty of room to keep pushing its cancer programs forward.
GPS and SLS009 are still the main characters
The biggest near-term catalyst is the Phase 3 REGAL trial of galinpepimut-S, or GPS, in acute myeloid leukemia. SELLAS said the final analysis will happen after the 80th event, which means the clock is still ticking before investors get a real readout.
Meanwhile, the Phase 2 study of SLS009 in newly diagnosed first-line AML has enrolled 28 patients, with topline data expected in Q4 2026. That gives the market a very specific reason to keep the ticker on the watchlist instead of letting it drift into biotech background noise.
A little more breathing room
SELLAS also said it ended June 30 with $138.3 million in cash and cash equivalents. For a development-stage biotech, that matters a lot — cash is runway, and runway is basically the difference between 'we have time for the science' and 'please check the shelf registration.'
What investors should watch next
- Final analysis timing for the REGAL trial
- Topline data from the SLS009 AML study in Q4 2026
- Any follow-up on the pancreatic cancer preclinical work
Big picture: this update didn’t hand investors a blockbuster result, but it did keep the clinical engine humming and the balance sheet looking sturdy. In biotech, that combo is often enough to keep hope — and volatility — very much alive.